Detalles de la búsqueda
1.
Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks.
J Allergy Clin Immunol
; 153(2): 479-486.e4, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37866460
2.
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
J Am Acad Dermatol
; 76(1): 70-80, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27707593
3.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
J Am Acad Dermatol
; 76(1): 60-69.e9, 2017 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-27663079
4.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
J Am Acad Dermatol
; 73(3): 400-9, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26092291
5.
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study.
Ann Rheum Dis
; 72(6): 863-9, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22730366
6.
Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results).
Dermatol Ther (Heidelb)
; 8(4): 571-579, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30334147
7.
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
J Rheumatol
; 41(3): 414-21, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-24429175
Resultados
1 -
7
de 7
1
Próxima >
>>